Study of treatment for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of stomach cancer called HER2-negative adenocarcinoma that hasn't spread to other organs.
- You are between 18 and 80 years old and able to do most daily activities without help.
- You have not had any chemotherapy, radiation, or other cancer treatment for this cancer yet.
- Your blood counts and liver/kidney function must be within a certain healthy range.
- You don't have any other serious health problems like uncontrolled heart disease, active infections, or a history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy (SOX) as a first treatment for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this combination can help shrink the tumor before surgery.
This trial tests a new combination of treatments for stomach cancer that has spread to the lining of the abdomen. It uses an immunotherapy drug (tislelizumab) with chemotherapy (SOX) and heated chemotherapy directly into the abdomen (HIPEC) to see if it works better than standard care.
This trial tests whether adding a drug called tislelizumab (an immunotherapy) to standard chemotherapy before and after surgery is better than chemotherapy alone for people with a specific type of stomach or GEJ cancer that has a high level of a marker called MHC class II. The goal is to see if it helps shrink the tumor and improves the chance of successful surgery.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy before and after surgery can help treat stomach or gastroesophageal junction cancer. It is for people whose cancer has not spread to other organs and who are well enough to have surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) and chemotherapy after surgery to prevent stomach cancer from coming back in older patients. It may be a good option for people who have had their cancer completely removed and are in good overall health.
This trial tests a combination of low-dose radiotherapy, chemotherapy, and an immunotherapy drug (tislelizumab) before and after surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Hear when a new Gastric Cancer, Gastroesophageal Junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.